Depression

A pioneer in cognitive behavior therapy shares his thoughts on a 50-year-long career.

The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) for treatment-resistant major depressive disorder has now demonstrated promise for reducing depressive symptoms of bipolar I disorder in an open-label feasibility and safety trial.

Patients with treatment resistant late-life depression are more likely to respond to antidepressants when sleep is sufficient or has improved.

Cognitive symptoms affect between 85% and 94% of patients with major depressive disorder. Despite this prevalence, cognitive dysfunction often remains undertreated and inadequately addressed in routine clinical practice.

Ketamine or ECT? A new study reveals which works best for severe depression—depending on the patient and setting.

Although diagnostic criteria for a depressive episode are the same for unipolar major depression and bipolar depression, these episodes differ in their natural history.

BLP-003, currently being evaluated for treatment-resistant depression and alcohol use disorder, today announced their global phase 2b clinical trial has completed patient enrollment.

Here are 10 things to consider when treating a patient with mood disorders.

After a lot of recent positive news for SPN-820, a recent phase 2b study shows the novel antidepressant failed to demonstrate a statistically significant improvement on the primary endpoint of change from baseline.

Learn more about the latest research on the impact the endocrine system has on major depressive disorder.

Check out these updates on research including major depressive disorder (MDD).

A recent phase 2b trial of GH001 showed promising results for treatment-resistant depression, demonstrating rapid and sustained effects with a favorable safety profile.

What patients are at risk when taking SSRIs?

Check out the pipeline updates from January!

Meditation using immersive virtual reality devices can help alleviate symptoms of major depressive disorder and generalized anxiety disorder.

How does affluence impact mental health outcomes?

Here are highlights from this week in Psychiatric Times, including FDA approvals and conference coverage.

The FDA has approved the supplemental New Drug Application for Spravato, the first and only monotherapy for adults with treatment-resistant depression.

Want to stay in the loop on the latest novel neuroplastogen for major depressive disorder, DLX-001? Check out this update.

While current antidepressants are associated with improved lives for patients, significant challenges arise. Do we need a new class of antidepressants to address these issues?

Choosing between these 2 interventions for patients with treatment-resistant depression may rest more on differences in access than in baseline characteristics.

Is there a way to separate the neuroplasticity and therapeutic effects from the hallucinatory and dissociative effects of traditional psychedelics?

DLX-001 is a novel neuroplastogen under development for the treatment of major depressive disorder. Learn more about the latest phase 1 data here.